Guillermo José Ruiz-Argüelles

Dr. Guillermo José Ruiz-Argüelles

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 1994 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
GRGuillermo José Ruiz-Argüelles
Guillermo José Ruiz-Argüelles
JMJesus F. San Miguel
Jesus F. San Miguel

9 July 2008 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
GRGuillermo José Ruiz-Argüelles
Guillermo José Ruiz-Argüelles
LTL C Tarin-Arzaga
L C Tarin-Arzaga
MGM L Gonzalez-Carrillo
M L Gonzalez-Carrillo
KGK I Gutierrez-Riveroll
K I Gutierrez-Riveroll
RRR Rangel-Malo
R Rangel-Malo
SGS Giralt
S Giralt

1 November 2016 in Archives of Medical Research
Verified
Journal Article
Closed access
RBRonald D. Barr
Ronald D. Barr
DGDavid Gomez-Almaguer
David Gomez-Almaguer
JJJose Carlos Jaime-Perez
Jose Carlos Jaime-Perez
GRGuillermo José Ruiz-Argüelles
Guillermo José Ruiz-Argüelles

12 January 2018 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
AKAmado Kardduss-Urueta
Amado Kardduss-Urueta
RGRobert Peter Gale
Robert Peter Gale
CGCesar Homero Gutierrez-Aguirre
Cesar Homero Gutierrez-Aguirre
MHMiguel Angel Herrera-Rojas
Miguel Angel Herrera-Rojas
IMIván Murrieta-Álvarez
Iván Murrieta-Álvarez
GRGuillermo José Ruiz-Argüelles
Guillermo José Ruiz-Argüelles

1 December 2003 in Acta Haematologica
Verified
Journal Article
Closed access
PDF file
GRGuillermo José Ruiz-Argüelles
Guillermo José Ruiz-Argüelles
DGDavid Gómez-Rangel
David Gómez-Rangel
GRGuillermo J. Ruiz-Delgado
Guillermo J. Ruiz-Delgado
ARAlejandro Ruiz-Argüelles
Alejandro Ruiz-Argüelles
BPBeatriz Pérez-Romano
Beatriz Pérez-Romano
LRLiliana Rivadeneyra
Liliana Rivadeneyra
Background: Methods to simplify the stem cell transplantation procedures are needed mainly in developing countries. We have previously shown that unprocessed leukapheresis material is useful to restore hematopoiesis after high-dose chemotherapy. Methods: Over a 10-year period in a private practice setting, we prospectively performed autotransplants using noncryopreserved and unmanipulated peripheral blood stem cells mobilized from the bone marrow to the peripheral blood by means of filgrastim and using a single-day conditioning regimen with high dose (200 mg/m2) melphalan. Results: Forty-six individuals were given 50 autografts. The median age of the patients was 33 years (range 8–69). Twenty-two patients with acute leukemia (13 with myeloblastic and 9 with lymphoblastic leukemia), 4 with chronic myelogenous leukemia, 6 with multiple myeloma, 7 with Hodgkin’s disease, 3 with non-Hodgkin’s lymphoma and 4 with metastatic breast carcinoma were included. The median time to achieve >0.5 × 109/l granulocytes was 14 days (range 0–86), whereas the median time to achieve >20 × 109/l platelets was 25 days (range 0–102). The 3,300-day posttransplant survival was 63%, the median posttransplant overall survival was over 3,300 days, the 3,300-day disease-free survival was 50% and the transplant-related mortality was 2%. The procedure was performed entirely on an outpatient basis in the case of 48 autografts (96%). The approximate cost of each graft was 7,500 USD. Conclusion: This simplified method to autograft patients, avoiding in-hospital stays, purging procedures and cryopreservation of the cells, is feasible and results in a substantial decrease in the cost of the autologous hematopoietic stem cell transplantation methods.

1 October 2018 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
ARAlejandro Ruiz-Argüelles
Alejandro Ruiz-Argüelles
MMMariana A. Méndez-Huerta
Mariana A. Méndez-Huerta
CLClaudia D. Lozano
Claudia D. Lozano
GRGuillermo José Ruiz-Argüelles
Guillermo José Ruiz-Argüelles